Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

NewGenIvf Group

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

JPMorgan analyst Cory Carpenter downgraded Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) stock from <a href="https://www.benzinga.com/quote/GETY/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>. The stock price declined after the rerating.
Getty Images is a leading visual content creator and marketplace that connects over 576,000 content creators with 719,000 purchasing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a>
The rerating reflects Getty Images stock trading at a healthy premium to Shutterstock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>), uncertainty around the potential longer-term impact from generative AI on the industry, potential growth headwinds in 2025 (lapping even-year events + FX) and limited capital allocation flexibility.
Getty Images returned to growth in recent quarters driven by a strong event calendar (U.S. election and Olympics), lapping easier Hollywood strike comps and agency channel stability.
Carpenter expects these trends to persist in the fourth quarter but noted the 2025 setup will be more challenging as the event calendar turns into a ~$10 million-$12 million headwind and Getty Images has high foreign exchange exposure relative to the rest of the analyst&#8217;s coverage universe.
Carpenter expects this to translate into limited revenue growth and margin expansion in 2025. This, coupled with ongoing uncertainty around the potential longer-term impact of generative AI on the industry, Getty Images trading at a healthy premium to Shutterstock, warrant litigation overhang and limited capital allocation flexibility, gives the analyst a cautious bias on the stock next year.
GETY Price Action: Getty Images stock is down 4.67% at $2.45 at publication Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a></li>
</ul>
Photo: Shutterstock

Downgrades

Price Target

Analyst Ratings

Movers

Media

GETY

SSTK

Getty Images' AI Uncertainty, FX Headwinds, Premium Valuation Spark Downgrade

WIIM

MULN

Mullen Automotive shares are trading higher after the company announced 100 Class 1 and Class 3 EV shipments for sales totaling $5.5 million. Additionally, the company reduced its monthly burn rate since August 2024

XCHG Shares Resume Trade Then Again Halted On Circuit Breaker To The Downside, Stock Now Down -92.2%

Nukkleus shares are trading higher on continued momentum after the company recently announced it has acquired a 51% controlling stake in Star 26 Capital.

Macquarie analyst Steve Koenig maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and maintains $370 price target.

Macquarie Maintains Neutral on Salesforce, Maintains $370 Price Target

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 387.2%

SMTK

SmartKem shares are trading higher after the company announced it received a £900,000 grant from Innovate UK and commenced a $7.65 million offering of common stock and Class D warrants.

JPMorgan analyst Doug Anmuth has rolled out an optimistic<a href="https://www.benzinga.com/markets/24/12/42497093/stock-market-predictions-for-2025-a-mixed-bag-of-expectations"> internet 2025 outlook</a>, emphasizing mega-cap tech leaders as top picks. The big winners? Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google, and Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>). 
Despite "heavy capex investments," Anmuth expects "increasing returns" as artificial intelligence shifts to practical applications, driving growth in advertising, cloud, and software tools.
<h2 class="wp-block-heading">Why 2025 Looks Promising</h2>
Anmuth highlights three transformative AI trends reshaping the tech landscape:
<ol>
<li>A 30% boost in engineering efficiency across major companies.</li>
<li>Billions in AI revenue for AWS and Google Cloud.</li>
<li>Accelerated ad and search growth for Meta and Google, driven by improved targeting and conversions.</li>
</ol>
These advancements, coupled with a pro-business political backdrop and stabilized macro trends, are set to support strong revenue growth across the Internet sector in 2025.
Read Also: <a href="https://www.benzinga.com/24/12/42556006/amazon-to-rally-around-21-here-are-10-top-analyst-forecasts-for-wednesday">Amazon To Rally Around 21%?</a>
<h2 class="wp-block-heading">Capex Surge: A Long-Term Play</h2>
Big tech is gearing up for significant infrastructure spending in 2025, exceeding market expectations. 
Anmuth projects capex of $97 billion for Amazon, $64 billion for Meta, and $62 billion for Alphabet. While these investments may weigh on margins, the long-term outlook remains bullish. 
Amazon and Alphabet are forecasted to expand margins and free cash flow, while Meta's outlook is steadier, despite double-digit revenue and EPS growth expectations.
<h2 class="wp-block-heading">Stock-Specific Highlights</h2>
<ul>
<li>Amazon (Target Price: $280) Amazon&#8217;s dominance in e-commerce and cloud markets positions it for multi-year margin and free cash flow expansion. With high-growth AWS and advertising streams, the company is poised to capitalize on untapped potential in IT and retail digitization.</li>
<li>Alphabet (Target Price: $232) Alphabet's ad business and AI-driven innovation keep it ahead of the pack. Search, YouTube ads, and cloud services present robust growth opportunities, while its "Other Bets" businesses like Waymo and Verily add optionality.</li>
<li>Meta Platforms (Target Price: $725) Meta's dual focus on AI and the metaverse underscores its commitment to long-term growth. Despite increased infrastructure spending, Meta's unmatched reach and targeting capabilities ensure sustained profitability and value for advertisers.</li>
<li>Spotify (Target Price: $555) Spotify continues to ride the audio streaming wave with solid user growth, cost discipline, and profit gains from podcasts and marketplace contributions.</li>
</ul>
As AI matures, these mega-cap tech leaders are well-positioned to reap the rewards of their massive investments. 
While elevated capex may challenge short-term margins, the broader narrative of innovation, efficiency, and market dominance paints a bullish picture for 2025. 
For investors, JPMorgan's favorites—Amazon, Meta, Alphabet, and Spotify—stand as compelling opportunities to capitalize on the next phase of tech evolution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42548075/us-stock-markets-outsized-influence-resurges-as-it-dominates-two-thirds-of-msci-world-indexs-capitalization-mirroring-late-1980s-peak">US Stocks Led By Apple, Nvidia, And Other Tech Giants Dominate Nearly Two-Thirds Of MSCI World Index, Drawing Parallels To 1980s Peak</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Long Ideas

Tech

AMZN

GOOG

GOOGL

SPOT

Amazon, Meta, Alphabet, Spotify Lead JPMorgan's 2025 Tech Picks For AI Potential

Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Instagram has the potential to generate 50% of the company&#8217;s advertising revenue in the U.S., Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-18/instagram-expected-to-generate-50-of-meta-s-us-ad-sales-in-2025?sref=TBDibEcD" rel="noreferrer noopener">cites</a> from Emarketer estimates.
Instagram could breach $32 billion in U.S. advertising revenue in 2025, up over 24% in 2024, as its short-form video product Reels gain traction, Bloomberg cites Emarketer. The video-sharing app boasts over 148 million American users.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a>
By early 2022, Instagram accounted for nearly 30%&nbsp;of Meta&#8217;s global business from 27% in 2021, Bloomberg cited court filings.
Reels competes with ByteDance&#8217;s TikTok and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube Shorts.
Meta&#8217;s focus on video content has been instrumental to its growth, as users devoted nearly 67% of their Instagram time to surfing videos, Bloomberg cited Jasmine Enberg of Emarketer.
<a target="_blank" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" rel="noreferrer noopener">The TikTok ban</a> could serve as a tailwind for Instagram, helping it win over 20% of reallocated TikTok ad dollars in the U.S, Reuters cites Enberg.
Meta previously told Instagram Reels accounted for over 50%&nbsp;of the time people spend on the app.
In 2024, 53.7% of Instagram&#8217;s ad revenue primarily came from its Feed features and 24.6% from Stories features. With Reels&#8217; revenue boost, the combined revenue share from Instagram Explore, Reels, and Threads could rise 9.6% in 2025.
In October, BofA Securities analyst Justin Post <a target="_blank" href="https://www.benzinga.com/news/24/10/41465662/metas-reels-monetization-and-ai-innovations-drive-top-ai-pick-analyst" rel="noreferrer noopener">projected Meta&#8217;s upside</a> from ramping up Messaging and Reel monetization powered by new artificial intelligence tools and CRM integration.
Meta Platforms stock surged 79% year-to-date. Investors can gain exposure to the stock through Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>) and The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>).
<h2 class="wp-block-heading">Is Meta A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), you'll notice that earnings in its last quarter grew 14.86% <a href="https://www.benzinga.com/quote/META/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
On the valuation side, Meta Platforms's price to earnings ratio &#8211; a measure of how much an investor pays for the company's earnings &#8211; is compressed 15.56% in the current quarter when compared with last year. That places it below similar businesses Alphabet, Baidu, Pinterest in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/META">Meta Platforms's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
Price Action: META stock is up 1.15% at $626.545 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42553094/jabil-q1-earnings-tops-expectations-cloud-and-data-center-growth-outlook" target="_blank" rel="noreferrer noopener">Jabil Q1 Earnings: Revenue And EPS Beat, Cloud and Data Center Growth, Raises Annual Outlook</a></li>
</ul>
Photo via Shutterstock

Instagram's Ad Revenue Could Hit $32 Billion by 2025, Driving Meta's Growth: Report

AZTA

Azenta shares are trading higher after Stephens & Co. upgraded the stock to Overweight from Equal-Weight and raised its price target from $50 to $60.

Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock is trading higher on Wednesday after the company announced it secured a 400 MWh <a href="https://www.benzinga.com//node/42552632">standalone storage order</a> with International Electric Power.
The Details: This order is part of a project to be deployed at Marine Corps Base Camp Pendleton in San Diego, California which aims to enhance grid resiliency for the U.S. Navy and Marine Corps.
The project, supported by funding from the California Energy Commission's Long Duration Energy Storage Program, will use Eos Z3 batteries and is scheduled for delivery beginning in 2025. The Eos Z3 Cubes are safe, non-flammable and don't require cooling systems, which helps minimize noise and reduce operational costs.
&#8220;IEP and CEC are at the forefront of North American long-duration energy storage, and their partnership has been invaluable as Eos transitions into a profitable operating company. They recognize the need for multiple storage technologies and the energy security that an American-made product provides,&#8221; added Joe Mastrangelo, Eos CEO.
&#8220;It&#8217;s an honor to have been selected for such an important installation at Camp Pendleton.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42557838/palantir-technologies-unusual-options-activity">Palantir Technologies Unusual Options Activity</a>
EOSE Price Action: At the time of writing Eos Energy stock is trading 14.7% higher at $4.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock

EOSE

What's Going On With Eos Energy Stock Wednesday?

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TH#TSX">TH</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV&#xAE; is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the <a href="https://www.globenewswire.com/Tracker?data=8zHQ9qiyFO30h9BOfieWluYkNSdMsyvq24uHfuCufIVJuAcz2MC2Wi8JwO3uxPJK5Zg4Hnxe9yRK0YL8b-VwzIBT6sI1dIqefPxyrQH9SQcGs96Be7BtzwxdO12cw4ciN0DBUaDXb2Ey9HpTsYJ1aBwYpdHX5l1dgbBweAE30nUjyjJdJMuySCqOg_9-Q9R4FdrlVrl3X8KTmjgYmunrjBVx1NwAWJWd66efKQ6DFRo=">recently manufactured</a> batches of&nbsp;EGRIFTA SV&#xAE;.
Existing inventory levels of&nbsp;EGRIFTA SV&#xAE; are expected to meet patient demand until mid-January 2025. Theratechnologies therefore continues discussions with the relevant FDA divisions in an effort to accelerate the release of EGRIFTA SV&#xAE; and avoid a product shortage at the patient level.
The Company will update the market on any further material developments.
EGRIFTA SV&#xAE; is distributed in the United States only.

Biotech

General

THTX

TSX:TH

Theratechnologies Has Submitted A Prior Approval Supplement To The U.S. FDA Describing The Changes Made To The Manufacturing Environment Of The Facility Where EGRIFTA SV Is Produced

QBTS

D-Wave Quantum shares are trading higher amid continued volatility in quantum stocks.

<a href="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr" title="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr">https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr</a>

Contracts

PYPL

Reported Earlier, 'Bureau Secures $30M From Sorenson Capital, PayPal Ventures, Existing Investors' - Economic Times

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

LNTH

P/E Ratio Insights for Lantheus Holdings

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 377%

Nukkleus Inc Shares Resume Trading

EGHT

8x8 shares are trading higher after Morgan Stanley raised its price target on the stock from $2 to $2.6.

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) heads into its <a href="https://www.benzinga.com/quote/MU/earnings">first-quarter earnings</a> announcement with a mix of optimism and caution.
<h1 class="wp-block-heading">"Choppy Quarters Ahead"?</h1>
As Jake Silverman, Bloomberg Intelligence Semiconductor Analyst, puts it, "choppy quarters ahead for NAND" could pose a challenge, with pricing and inventory pressures in the smartphone and PC markets.
However, the analyst also highlights AI-related applications as a potential offset, giving Micron a chance to weather the storm.
Read Also: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
<h1 class="wp-block-heading">Bullish Technical Signals Keep Optimists In The Game</h1>
Micron's stock, currently trading at $110.93, flashes bullish signs across key technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png" alt="" class="wp-image-698134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
It sits well above short- and medium-term moving averages, with the eight-day simple moving average (SMA) at $103.94, the 20-day SMA at $102.07 and the 50-day SMA at $104.07. 
The Moving Average Convergence Divergence (MACD) at 1.15 also suggests momentum is on the bulls' side.
However, the 200-day SMA of $110.93 coincides with the price, remaining a hurdle, signaling a potential resistance level.
<h1 class="wp-block-heading">AI: A Light At The End Of The NAND Tunnel?</h1>
The market will be laser-focused on how Micron balances the dynamics of two divergent forces:
<ol>
<li>NAND Weakness: Elevated inventories and pricing pressure.</li>
<li>AI Opportunities: As Silverman notes, secular growth in AI applications could provide a much-needed boost, potentially offsetting the broader NAND market challenges.</li>
</ol>
<h1 class="wp-block-heading">What's Expected?</h1>
Analysts estimate an EPS of $1.76 and revenue of $8.72 billion. But beyond these numbers, investors will be scrutinizing the company's guidance. Can Micron sustain its AI-driven growth momentum, or will "choppy quarters" in NAND drag it down?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/12/42549182/us-stocks-to-open-higher-as-rate-cut-expectations-surge-all-eyes-on-dow-jones-to-break-its-9-day-losing-streak">US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak</a></li>
</ul>
Photo: NPS_87 on Shutterstock

Technicals

Previews

Micron Earnings: Will AI Growth Outweigh 'Choppy' Memory Market?

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 319.6%

NOTV, BFRI and CPOP among pre-market losers

SPWR, BIG and BOLT among pre-market losers

NewGenIvf receives Nasdaq non-compliance notifications

NewGenIvf updates on potential reverse merger with COVIRIX

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

NewGenIvf surges after binding term sheet news with White Lion for $100M equity line of credit

NewGenIvf Group (NIVF) has entered into a binding term sheet with White Lion Capital, setting out the principal terms and conditions for a $100 mil...

NewGenIvf Group enters binding term sheet with White Lion Capital

NewGenIvf gets delisting notice from Nasdaq

NewGenIvf Group (NIVF) announced that on November 21 2024, it received written notice from The Nasdaq Stock Market that its securities are subject ...

NewGenIvf Group receives Nasdaq delisting notice, plans to appeal

NewGenIvf Group (NIVF) has entered into a binding term sheet regarding the previously announced proposed reverse merger with healthcare company Eur...

NewGenIvf Group announces proposed reverse merger with EWIHL

ACIU

ALLR

ATCH

ATIP

ATPC

AZTR

BBLG

BFRI

BOLT

CJET

CONN

CPOP

CTNT

DRMA

HOLO

HOTH

KOSS

NOTV

NUZE

OKLO

PIRS

PMNT

RYDE

SAGE

SLRX

SOAR

SPWR

VRPX

VSTM

VTAK

Health Care

The Search Is Over: NewGenIVF Inks Reverse Merger Agreement With European Wellness Investment Holdings

Press Releases

NewGenIvf Provides Update on Potential Reverse Merger with COVIRIX

NewGenIvf Announces Filing of 2023 Annual Report with the SEC

NewGenIvf Receives Nasdaq Notification Regarding Minimum Bid Price

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Financing

NewGenIvf Enters into a Binding Term Sheet with White Lion Capital for $100 Million Equity Line of Credit, Expandable to $500 Million

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

NewGenIvf Receives Nasdaq Delisting Notice and Plans to Submit Appeal, Announces Strategic Path Forward to Regain Compliance

NewGen Signs Binding Term Sheet for Reverse Merger with European Wellness Investment Holdings

AGBA

APLM

BNZI

BREA

CRDL

DRUG

HCWB

ILLR

NIXX

PRSO

RANI

SINT

STAF

TVGN

VMAR

VSME

XPON

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Comments

NewGenIvf Group

Noticias

Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL